A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 38/48 (2006.01) A61K 38/19 (2006.01) A61K 38/20 (2006.01) A61K 38/36 (2006.01) A61K 38/39 (2006.01) A61K 48/00 (2006.01)
Patent
CA 2335038
The present invention relates generally to the fields of angiogenesis and cancer therapy. More particularly, it concerns the use of anti-angiogenic factors in cancer therapy. The present invention demonstrates that angiostatin or endostatin can sensitize a cell to radiation therapy. Methods and compositions for inhibiting growth, sensitizing a cell to radiotherapy and treating cancer growth by first inhibiting angiogenesis and then employing radiotherapy are described.
La présente invention se rapporte aux domaines de l'angiogenèse et des thérapies anticancéreuses. Elle porte plus particulièrement sur l'utilisation de facteurs anti-angiogéniques dans les thérapies anticancéreuses. Cette invention démontre que l'angiostatine ou l'endostatine peut sensibiliser une cellule à une radiothérapie. L'invention porte également sur des procédés et des compositions visant à inhiber la prolifération des cellules cancéreuses, sensibiliser une cellule à une radiothérapie et traiter la prolifération des cellules cancéreuses en inhibant d'abord l'angiogenèse et en effectuant ensuite une radiothérapie.
Kufe Donald W.
Sukhatme Vikas P.
Weichselbaum Ralph R.
Arch Development Corporation
Beth Israel Deaconess Medical Center Inc.
Dana-Farber Cancer Institute
Torys Llp
LandOfFree
Combination of radiotherapy and anti-angiogenic factors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combination of radiotherapy and anti-angiogenic factors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination of radiotherapy and anti-angiogenic factors will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1588418